Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 safety study of GRNOPC1 in patients with neurologically complete, subacute, spinal cord injury

Trial Profile

A Phase 1 safety study of GRNOPC1 in patients with neurologically complete, subacute, spinal cord injury

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OPC 1 (Primary)
  • Indications Spinal cord injuries
  • Focus Adverse reactions; First in man
  • Sponsors Asterias Biotherapeutics
  • Most Recent Events

    • 31 Jul 2018 Updated results from the 25 subjects (SCiStar study) and 5 subjects from this Phase 1 safety study are presented in an Asterias Biotherapeutics media release.
    • 21 Mar 2017 Results published in an Asterias Biotherapeutics media release.
    • 21 Jun 2016 According to an Asterias Biotherapeutics media release, the results of this trial will be presented at the 2016 International Society for Stem Cell Research (ISSCR) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top